In short
PRX005, also known as BMS-986446, is an innovative anti-MTBR Tau monoclonal antibody currently being studied in clinical trials for the treatment of early Alzheimer's Disease. This article explores the ongoing Phase 2 clinical trial, known as TargetTau-1, which aims to evaluate the efficacy, safety, and tolerability of PRX005 in patients with early-stage Alzheimer's. The study focuses on assessing changes in cognitive function and brain tau deposition, offering hope for potential breakthroughs in Alzheimer's treatment.
At a glance
- Drug Name
- PRX005 (BMS-986446)
- Drug Type
- Anti-MTBR Tau Monoclonal Antibody
- Trial Phase
- Phase 2
- Target Condition
- Early Alzheimer's Disease
- Main Objective
- Change in thinking and general functioning at Week 76
- Primary Endpoint
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score
- Key Secondary Endpoints
- Change in brain tau deposition, integrated Alzheimer's Disease Rating Scale (iADRS) score
- Administration
- Intravenous injection
- Key Inclusion Criteria
- MCI due to AD or mild AD dementia, CDR score 0.5-1.0, MMSE score 22-30
- Key Exclusion Criteria
- Other conditions affecting cognition, contraindications to PET or MRI imaging
What is PRX005?
PRX005 is a new medication being studied for the treatment of early Alzheimer's disease. It is also known by its sponsor product code BMS-986446 or as an Anti-MTBR-Tau mAb (monoclonal antibody). This means it's a type of antibody that targets a specific part of the tau protein in the brain, which is believed to play a role in Alzheimer's disease.
How PRX005 Works
PRX005 is designed to target the MTBR (microtubule binding region) of the tau protein. In Alzheimer's disease, tau proteins can accumulate and form tangles in the brain, which are thought to contribute to the progression of the disease. By targeting these tau proteins, PRX005 aims to slow down or potentially halt the progression of early Alzheimer's disease.
Current Research on PRX005
PRX005 is currently being studied in a Phase 2 clinical trial called TargetTau-1. This is a global study designed to evaluate how well PRX005 works and how safe it is for people with early Alzheimer's disease. The study is:
- Randomized: Participants are randomly assigned to either receive PRX005 or a placebo (a substance with no active medication).
- Double-blind: Neither the participants nor the researchers know who is receiving PRX005 or the placebo during the study.
- Placebo-controlled: Some participants receive a placebo to compare the effects with those who receive PRX005.
Who Can Participate in the PRX005 Study?
The study is looking for people with early Alzheimer's disease. To be eligible, participants must meet several criteria, including:
- Having mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease dementia. This means people who are starting to have memory problems or other cognitive issues, but can still perform most daily activities.
- Scoring between 0.5 and 1.0 on the Global Clinical Dementia Rating (CDR) scale. This scale measures the severity of dementia symptoms.
- Having evidence of Alzheimer's disease pathology in the brain. This might be determined through brain scans or other tests.
- Showing impairment in memory tests, specifically scoring at least one standard deviation below the age-adjusted mean on a specific memory test (Wechsler Memory Scale IV-Logical Memory Subtest II).
- Having a score of 22 to 30 on the Mini Mental Status Examination (MMSE). This is a test that assesses cognitive function.
There are also several factors that would exclude someone from participating in the study, such as having other conditions that affect cognition, or not being able to undergo certain types of brain scans.
Study Objectives and Measurements
The main goal of the study is to see how PRX005 affects thinking abilities and general functioning in people with early Alzheimer's disease. Researchers will measure this using a scale called the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) after 76 weeks of treatment.
The study will also look at several other factors, including:
- Changes in tau protein buildup in the brain, measured using PET scans (a type of brain imaging).
- Changes in cognitive function and daily living activities, measured by various tests and scales.
- The safety of PRX005 and how well patients tolerate it.
Potential Benefits of PRX005
While it's important to note that PRX005 is still in the research phase and its benefits are not yet proven, the hope is that it could potentially:
- Slow down the progression of early Alzheimer's disease
- Improve or maintain cognitive function in people with early Alzheimer's
- Help people with early Alzheimer's maintain their ability to perform daily activities
However, more research is needed to determine if PRX005 is safe and effective for treating early Alzheimer's disease. The ongoing clinical trial will provide valuable information about this potential new treatment.